Raffanti S,Haas DW,Limbird LE,Hardman JE,Gilman AF,McGraw‑Hill AF .2001 .Antimicrobial agents (continued) antiretroviral agent. Goodman and Gilman's the Pharmacological Basis of Therapeutics, : 1349.
Flexner C. .2007 .HIV drug development: The next 25 years. Nat Rev Drug Discov, 6 : 959-66.
Fact Sheet USAID .2014 .. Last accessed on 2015 Dec, 31 : .
Progress Report Nepal Country .2015 .. _report_2015.pdf. [Last accessed on 2015 Dec, 31 : .
Date HL,Fisher M,Walker R,Edwards C .2003 .. Clinical Pharmacy and Therapeutics, 600 : 608.
Gallant JE .2002 .Initial therapy of HIV infection. J Clin Virol, 25 : 317-33.
Mokrzycki MH,Harris C,May H,Laut J,Palmisano J .2000 .Lactic acidosis associated with stavudine administration: A report of five cases. Clin Infect Dis, 30 : 198-200.
Bonfanti P,Ricci E,Landonio S,Valsecchi L,Timillero L,Faggion I .2001 .Predictors of protease inhibitora‑ssociated adverse events. Biomed Pharmacother, 55 : 321-3.
Martinez E,Mocroft A,GarcíaV‑iejo MA,Pérez‑Cuevas JB,Blanco JL,Mallolas J .2001 .Risk of lipodystrophy in HIV1‑i‑nfected patients treated with protease inhibitors: A prospective cohort study. Lancet, 357 : 592-8.
Mocroft A,Youle M,Moore A,Sabin CA,Madge S,Lepri AC .2001 .Reasons for modification and discontinuation of antiretrovirals: Results from a single treatment centre. AIDS, 15 : 185-94.
Ammassari A,Murri R,Pezzotti P,Trotta MP,Ravasio L,De Longis P .2001 .Self‑reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr, 28 : 445-9.
d'Arminio Monforte A,Lepri AC,Rezza G,Pezzotti P,Antinori A,Phillips AN .2000 .Italian Cohort of Antiretroviral‑Naïve Patients. AIDS, 14 : 499-507.
Harb GE,Alldredge BK,Coleman R,Jacobson MA .1993 .Pharmacoepidemiology of adverse drug reactions in hospitalized patients with human immunodeficiency virus disease. J Acquir Immune Defic Syndr, 6 : 9192-6.
Moore RD,Fortgang I,Keruly J,Chaisson RE .1996 .Adverse events from drug therapy for human immunodeficiency virus disease. Am J Med, 101 : 34-40.
Carr A,Cooper DA .2000 .Adverse effects of antiretroviral therapy. Lancet, 356 : 1423-30.
Kaufmann D,Pantaleo G,Sudre P,Telenti A .1998 .‑cell count in HIV‑1‑infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort Study. Lancet, 351 : 723-4.
Danner SA,Carr A,Leonard JM,Lehman LM,Gudiol F,Gonzales J .1995 .A short‑term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV‑1 protease. N Engl J Med, 333 : 1528-33.
Fischl MA,Stanley K,Collier AC,Arduino JM,Stein DS,Feinberg JE .1995 .Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group. Ann Intern Med, 122 : 24-32.
Hammer SM,Saag MS,Schechter M,Montaner JS,Schooley RT,Jacobsen DM .2006 .Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society‑USA panel. JAMA, 296 : 827-43.
Hennessy S,Strom BL,Berlin JA,Brennan PJ .1995 .Predicting cutaneous hypersensitivity reactions to cotrimoxazole in HIV‑infected individuals receiving primary Pneumocystis carinii pneumonia prophylaxis. J Gen Intern Med, 10 : 380-6.
Tedaldi EM,Absalon J,Thomas AJ,Shlay JC .2008 .Ethnicity, race, and gender. Differences in serious adverse events among participants in an antiretroviral initiation trial: Results of CPCRA 058 (FIRST Study). J Acquir Immune Defic Syndr, 47 : 4418.
Haas DW,Ribaudo HJ,Kim RB,Tierney C,Wilkinson GR,Gulick RM .2004 .Pharmacogenetics of efavirenz and central nervous system side effects: An Adult AIDS Clinical Trials Group study. AIDS, 18 : 2391-400.
Mensah GA,Mokdad AH,Ford ES,Greenlund KJ,Croft JB .2005 .State of disparities in cardiovascular health in the United States. Circulation, 111 : 1233-41.
Roudiére L,Viard JP .2056 .Osteonecrosis of the hip, lipodystrophy and antiretroviral treatment. AIDS, 14 : .
Knobel H,Guelar A,Vallecillo G,Nogués X,Díez A .2001 .Osteopenia in HIV‑infected patients: Is it the disease or is it the treatment. AIDS, 15 : 807-8.
Bruno R,Sacchi P,Puoti M,Soriano V,Filice G. .2002 .HCV chronic hepatitis in patients with HIV: Clinical management issues. Am J Gastroenterol, 97 : 1598-606.
Malavaud B,Dinh B,Bonnet E,Izopet J,Payen JL,Marchou B .2000 .Increased incidence of indinavir nephrolithiasis in patients with hepatitis B or C virus infection. Antivir Ther, 5 : 3-5.
Sulkowski MS,Thomas DL,Chaisson RE,Moore RD .2000 .Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA, 283 : 74-80.
Kontorinis N,Dieterich D. .2003 .Hepatotoxicity of antiretroviral therapy. AIDS Rev, 5 : 36-43.
Lee EC,Walmsley S,Fantus IG .1999 .New‑onset diabetes mellitus associated with protease inhibitor therapy in an HIV‑positive patient: Case report and review. CMAJ, 161 : 161-4.
Brown T T,Li X,Cole SR,Kingsley L A,Palella FJ,Riddler SA .2005 .Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS, 19 : 1375-83.
Farrell GC .2002 .Drugs and steatohepatitis. Semin Liver Dis, 22 : 185-94.
Carr A,Samaras K,Burton S,Law M,Freund J,Chisholm DJ .1998 .A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS, 12 : F51-8.
Mauss S. .2000 .HIV‑associated lipodystrophy syndrome. AIDS, 14(Suppl 3) : S197-207.
Tavassoli N,Bagheri H,Sommet A,Delpierre C,Marion‑Latard F,Massip P .2006 .Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus‑related fat redistribution evaluated by dual‑energy x‑ray absorptiometr y. Pharmacotherapy, 26 : 154-61.
Anonymous .2007 .Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med, 356 : 1723-35.
Walmsley S,Bernstein B,King M,Arribas J,Beall G,Ruane P .2002 .Lopinavir‑ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med, 346 : 2039-46.
Montessori V,Press N,Harris M,Akagi L,Montaner JS .2004 .Adverse effects of antiretroviral therapy for HIV infection. CMAJ, 170 : 229-38.
Hollmig KA,Beck SB,Doll DC .2001 .Severe bleeding complications in HIV‑positive haemophiliac patients treated with protease inhibitors. Eur J Med Res, 6 : 112-4.
Kodoth S,Bakshi S,Scimeca P,Black K,Pahwa S K .2001 .Possible linkage of amprenavir with intracranial bleeding in an HIV‑infected hemophiliac. AIDS Patient Care STDS, 15 : 347-52.
Dybul M,Fauci AS,Bartlett JG,Kaplan JE,Pau AK .2002 .Panel on Clinical Practices for Treatment of HIV. Guidelines for using antiretroviral agents among HIV‑infected adults and adolescents. Ann Intern Med, 137(5 Pt 2) : 381-433.
Roujeau JC,Stern RS .1994 .Severe adverse cutaneous reactions to drugs. N Engl J Med, 331 : 1272-85.
D'Aquila RT,Hughes MD,Johnson VA,Fischl MA,Sommadossi JP,Liou SH .1996 .Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV‑1 infection. A randomized, doubleb‑lind, placeboc‑ontrolled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Ann Intern Med, 124 : 1019-30.
Saltel E,Angel JB,Futter NG,Walsh WG,O'Rourke K,Mahoney JE .2000 .Increased prevalence and analysis of risk factors for indinavir nephrolithiasis. J Urol, 164 : 1895-7.
Bräu N,Leaf HL,Wieczorek RL,Margolis DM .1997 .Severe hepatitis in three AIDS patients treated with indinavir. Lancet, 349 : 924-5.
Picard O,Rosmorduc O,Cabane J .1998 .Hepatotoxicity associated with ritonavir. Ann Intern Med, 129 : 6701.
Piroth L,Grappin M,Sgro C,Buisson M,Duong M,Chavanet P. Recurrent NNRTI .2000 .‑induced hepatotoxicity in an HIV‑HCV‑coinfected patient. Ann Pharmacother, 34 : 534-5.
Carr A,Miller J,Law M,Cooper DA M .2000 .A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitorr‑elated lipodystrophy syndrome. AIDS, 14 : F25-32.
Bonnet F,Balestre E,Bernardin E,Pellegrin JL,Neau D,Dabis F .2005 .Risk factors for hyperlactataemia in HIV‑infected patients. Antivir Chem Chemother, 16 : 63-7.
John M,Moore CB,James IR,Nolan D,Upton RP,McKinnon EJ .2001 .Chronic hyperlactatemia in HIV‑infected patients taking antiretroviral therapy. AIDS, 15 : 717-23.
Chattha G,Arieff AI,Cummings C,Tierney LM .1993 .Lactic acidosis complicating the acquired immunodeficiency syndrome. Ann Intern Med, 118 : 37-9.
Watts DH .2007 .Teratogenicity risk of antiretroviral therapy in pregnancy. Curr HIV/AIDS Rep, 4 : 135-40.
Wulff EA,Wang AK,Simpson DM .2000 .HIV‑associated peripheral neuropathy: Epidemiology, pathophysiology and treatment. Drugs, 59 : 1251-60.
Adkins JC,Noble S.,Efavirenz S. .1998 .. Drugs, 56 : 1055-64.
Clifford DB,Evans S,Yang Y,Acosta EP,Goodkin K,Tashima K .2005 .Impact of efavirenz on neuropsychological performance and symptoms in HIV‑infected individuals. Ann Intern Med, 143 : 714-21.
Dalakas MC .2001 .Peripheral neuropathy and antiretroviral drugs. J Peripher Nerv Syst, 6 : 14-20.
Simpson DM,Tagliati M. Nucleoside DM .1995 .‑ssociated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol, 9 : 153-61.
Blum AS,Dal Pan GJ,Feinberg J,Raines C,Mayjo K,Cornblath DR .1996 .Low‑dose zalcitabine‑related toxic neuropathy: Frequency, natural history, and risk factors. Neurology, 46 : 999-1003.
Dolin R,Amato DA,Fischl MA,Pettinelli C,Beltangady M,Liou SH .1995 .Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group. Arch Intern Med, 155 : 961-74.
Shelburne SA,Hamill RJ .2003 .The immune reconstitution inflammatory syndrome. AIDS Rev, 5 : 67-79.
French MA,Price P,Stone SF .2004 .Immune restoration disease after antiretroviral therapy. AIDS, 18 : 1615-27.
Mehta N,Reilly M. .2005 .Atherosclerotic cardiovascular disease risk in the HAART‑treated HIV‑1 population. HIV Clin Trials, 6 : 5-24.
Hester EK,Chandler HV,Sims KM .2006 .Fosamprenavir: Drug development for adherence. Ann Pharmacother, 40 : 1301-10.
Karras A,Lafaurie M,Furco A,Bourgarit A,Droz D .2003 .Tenofovir‑related nephrotoxicity in human immunodeficiency virus infected patients: Three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis, 36 : 1070-3.
Wislez M,Bergot E,Antoine M,Parrot A,Carette MF,Mayaud C .2001 .Acute respiratory failure following HAART introduction in patients treated for Pneumocystis carinii pneumonia. Am J Respir Crit Care Med, 164 : 8475-1.
Fellay J,Boubaker K,Ledergerber B,Bernasconi E,Furrer H,Battegay M .2001 .Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet, 358 : 1322-7.
Carr A,Samaras K,Thorisdottir A,Kaufmann GR,Chisholm DJ,Cooper DA .1999 .Diagnosis, prediction, and natural course of HIV‑1 protease‑inhibitor‑associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet, 353 : 2093-9.
Fortgang IS,Belitsos PC,Chaisson RE,Moore RD .1995 .Hepatomegaly and steatosis in HIV‑infected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol, 90 : 1433-6.
den Brinker M,Wit FW,Wertheim‑van Dillen PM,Jurriaans S,Weel J,van Leeuwen R .2000 .Hepatitis B and C virus co‑infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV‑1 infection. AIDS, 14 : 2895-902.
Scribner AN,Troia‑Cancio PV,Cox BA,Marcantonio D,Hamid F .2000 .Osteonecrosis in HIV: A casec‑ontrol study. J Acquir Immune Defic Syndr, 25 : 19-25.
Clay PG .2002 .The abacavir hypersensitivity reaction: A review. Clin Ther, 24 : 1502-14.
Hewitt RG .2002 .Abacavir hypersensitivity reaction. Clin Infect Dis, 34 : 1137-42.
Lopez AD,Mathers CD,Ezzati M,Jamison DT,Murray CJ .2006 .Global and regional burden of disease and risk factors, 2001: Systematic analysis of population health data. Lancet, 367 : 1747-57.
Henry K. .2000 .The case for more cautious, patient‑focused antiretroviral therapy. Ann Intern Med, 132 : 3061-1.
Shigdel R,Klouman E,Bhandari A,Ahmed LA .2014 .Factors associated with adherence to antiretroviral therapy in HIV‑infected patients in Kathmandu District, Nepal. HIV AIDS (Auckl), 6 : 109-16.
Bam K,Rajbhandari RM,Karmacharya DB,Dixit SM .2015 .Strengthening adherence to antiretroviral therapy (ART) monitoring and support: Operation research to identify barriers and facilitators in Nepal. BMC Health Serv Res, 15 : 188.
Programmatic .2015 .35_ eng. pdf?ua=1. [Last accessed on 2016 Apr, 01 : .
Günthard HF,Aberg JA,Eron JJ,Hoy JF,Telenti A,Benson CA .2014 .Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society‑USA Panel. JAMA, 312 : 410-25.
Services Human . .Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV1‑I‑nfected Adults and Adolescents. [Last accessed on 2016 Apr, 01 : .